Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Pregnancy and Sickle Cell Disease: A Review of the Current Literature
source: Critical Reviews in Oncology/Hematology
year: 2016
authors: Boga C, Ozdogu H
summary/abstract:Sickle cell disease (SCD) is the most common hereditary disease worldwide, presenting with anemia and intermittent severe pain. Pregnancy in a patient with SCD is associated with high levels of maternal and fetal morbidity and mortality; the maternal and fetal death rates during pregnancy can attain 11.4% and 20%, respectively. Patient care has improved over time. However, certain management issues remain unresolved; these include the optimum policy in terms of prophylactic blood transfusion, and the use of antiplatelet drugs. Such issues are attributable to the heterogeneous nature of clinical SCD features, and the limitations of uncontrolled and prospective trials. In this review, we seek to facilitate a better understanding of relevant issues via creation of a comparative data profile extracted from current studies. This report may also encourage the drafting of standard operating procedure for management of pregnancy in SCD patients.
organization: Baskent University Faculty of Medicine, Ankara, TurkeyDOI: 10.1016/j.critrevonc.2015.11.018
read more full text
+myBinderRelated Content
-
Sickle Cell Disease: Treatments – PAINWeekhttps://www.youtube.com/watch?v=llqCdRNK...
-
Sickle cell trait may not contribute to stroke riskSickle cell trait may not be an ...
-
Unanticipated consequences identified after implementation of a pediatric emergency department (PED)-based intranasa...Background: The 2014 National Heart Lun...
-
What Are the Signs and Symptoms of Sickle Cell Disease?If a person has sickle cell disease (SCD...
-
Research Team Recognized for Organ-on-a-Chip DesignSCD is a group of genetic disorders that...
-
Today’s Faces of Sickle Cell Disease: Jennelle StephensonJennelle Stephenson was diagnosed with S...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.